Core Insights - Cardinal Health reported a strong second quarter for fiscal year 2026, with revenues of $65.6 billion, a 19% increase from the previous year, and non-GAAP operating earnings rising 38% to $877 million [1][2][10] Financial Performance - Revenue for Q2 FY26 was $65.6 billion, up from $55.3 billion in Q2 FY25, reflecting a 19% year-over-year growth [2] - GAAP operating earnings increased by 29% to $707 million, while GAAP diluted EPS rose 19% to $1.97 [1][2] - Non-GAAP diluted EPS increased 36% to $2.63, driven by higher non-GAAP operating earnings and a lower share count [1][2] Segment Results - **Pharmaceutical and Specialty Solutions Segment**: Revenue increased 19% to $60.7 billion, with segment profit rising 29% to $687 million, attributed to growth in brand and specialty pharmaceutical sales [3][4] - **Global Medical Products and Distribution Segment**: Revenue grew 3% to $3.3 billion, with segment profit surging 106% to $37 million, driven by existing customer volume growth and cost optimization initiatives [5][6] - **Other Segment**: Revenue increased 34% to $1.7 billion, with segment profit up 52% to $179 million, supported by growth in at-Home Solutions and other operating segments [7][8] Fiscal Year 2026 Outlook - Cardinal Health raised its fiscal year 2026 guidance for non-GAAP diluted EPS to a range of $10.15 to $10.35, reflecting a growth of 23% to 26% [9][10] - Segment profit growth expectations were adjusted: Pharmaceutical and Specialty Solutions to 20%-22%, Global Medical Products and Distribution to approximately $150 million, and Other segment to 33%-35% [11] Share Repurchase and Acquisitions - The company completed a $375 million accelerated share repurchase program in Q2 FY26, totaling $750 million in share repurchases for the fiscal year [20] - Cardinal Health's Specialty Alliance acquired Solaris Health, enhancing its multi-specialty MSO platform [20]